If you could vote on Brexit now which option would you choose?
   

Moderna COVID vaccine sales forecast unchanged even as COVAX program cuts orders


Moderna Inc on Wednesday maintained its full-year COVID-19 vaccine sales forecast of $21 billion as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders. Moderna shares jumped nearly 17% in morning trading after the company also announced a $3 billion share buyback plan. Moderna has begun producing a redesigned booster shot targeting both the original coronavirus as well as the BA.4 and BA.5 Omicron subvariants.

Reuters - August 4, 2022

View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-retains-covid-vaccine-sales-view-weak-demand-low-income-nations-2022-08-03/